(Q41195395)

English

Gene transfer provides a practical means for safe, long-term, targeted delivery of biologically active neurotrophic factor proteins for neurodegenerative diseases

scientific article published on October 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 September 2017

Gene transfer provides a practical means for safe, long-term, targeted delivery of biologically active neurotrophic factor proteins for neurodegenerative diseases (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 September 2017

neurodegeneration

1 reference

based on heuristic

inferred from title

Jeffrey H Kordower

5

object named as

Jeffrey H Kordower

1 reference

Europe PubMed Central

PubMed publication ID

28 September 2017

author name string

Christopher D Herzog

1

1 reference

Europe PubMed Central

PubMed publication ID

28 September 2017

Kathie M Bishop

2

1 reference

Europe PubMed Central

PubMed publication ID

28 September 2017

Lamar Brown

3

1 reference

Europe PubMed Central

PubMed publication ID

28 September 2017

Alistair Wilson

4

1 reference

Europe PubMed Central

PubMed publication ID

28 September 2017

Raymond T Bartus

6

1 reference

Europe PubMed Central

PubMed publication ID

28 September 2017

publication date

1 October 2011

1 reference

Europe PubMed Central

PubMed publication ID

28 September 2017

Drug delivery and translational research

1 reference

Europe PubMed Central

PubMed publication ID

28 September 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

28 September 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

28 September 2017

361-382

1 reference

Europe PubMed Central

PubMed publication ID

28 September 2017

https://scigraph.springernature.com/pub.10.1007/s13346-011-0037-z

0 references

Neurotrophic molecules

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0037-Z

21 January 2018

Neurotrophins: roles in neuronal development and function

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0037-Z

21 January 2018

Nerve growth factor signaling, neuroprotection, and neural repair

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0037-Z

21 January 2018

Function of neurotrophic factors in the adult and aging brain and their possible use in the treatment of neurodegenerative diseases

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0037-Z

21 January 2018

Amelioration of cholinergic neuron atrophy and spatial memory impairment in aged rats by nerve growth factor.

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0037-Z

21 January 2018

Neurotrophic factors: can the degenerating brain be induced to heal itself?

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0037-Z

21 January 2018

A double-blind placebo-controlled clinical trial of recombinant human brain-derived neurotrophic factor (rhBDNF) in diabetic polyneuropathy

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0037-Z

21 January 2018

A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. rhCNTF ALS Study Group

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0037-Z

21 January 2018

Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0037-Z

21 January 2018

Nerve growth factor for the treatment of diabetic neuropathy: what went wrong, what went right, and what does the future hold?

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0037-Z

21 January 2018

Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD.

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0037-Z

21 January 2018

Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0037-Z

21 January 2018

Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0037-Z

21 January 2018

Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0037-Z

21 January 2018

Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0037-Z

21 January 2018

Hyperplastic changes within the leptomeninges of the rat and monkey in response to chronic intracerebroventricular infusion of nerve growth factor

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0037-Z

21 January 2018

Crossroads in GDNF therapy for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0037-Z

21 January 2018

Point source concentration of GDNF may explain failure of phase II clinical trial

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0037-Z

21 January 2018

Atrophy of cholinergic basal forebrain neurons following excitotoxic cortical lesions is reversed by intravenous administration of an NGF conjugate

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0037-Z

21 January 2018

NGF as a mediator of inflammatory pain.

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0037-Z

21 January 2018

Neurotrophins: mediators and modulators of pain.

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0037-Z

21 January 2018

Improving protein therapeutics with sustained-release formulations

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0037-Z

21 January 2018

Intraventricular infusion of nerve growth factor as the cause of sympathetic fiber sprouting in sensory ganglia

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0037-Z

21 January 2018

Six-month continuous intraputamenal infusion toxicity study of recombinant methionyl human glial cell line-derived neurotrophic factor (r-metHuGDNF in rhesus monkeys

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0037-Z

21 January 2018

Eight years of clinical improvement in MPTP-lesioned primates after gene therapy with AAV2-hAADC.

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0037-Z

21 January 2018

Pharmaceutical treatment for cognitive deficits in Alzheimer's disease and other neurodegenerative conditions: exploring new territory using traditional tools and established maps

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0037-Z

21 January 2018

The cholinergic hypothesis of geriatric memory dysfunction

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0037-Z

21 January 2018

On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0037-Z

21 January 2018

Parkinson's disease. First of two parts

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0037-Z

21 January 2018

Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0037-Z

21 January 2018

AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0037-Z

21 January 2018

Issues regarding gene therapy products for Parkinson's disease: the development of CERE-120 (AAV-NTN) as one reference point

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0037-Z

21 January 2018

Therapeutic potential of CERE-110 (AAV2-NGF): targeted, stable, and sustained NGF delivery and trophic activity on rodent basal forebrain cholinergic neurons

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0037-Z

21 January 2018

Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys.

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0037-Z

21 January 2018

Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0037-Z

21 January 2018

Transgene expression, bioactivity, and safety of CERE-120 (AAV2-neurturin) following delivery to the monkey striatum

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0037-Z

21 January 2018

Locomotion of aged rats: relationship to neurochemical but not morphological changes in nigrostriatal dopaminergic neurons.

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0037-Z

21 January 2018

Normal and drug-induced locomotor behavior in aging: comparison to evoked DA release and tissue content in fischer 344 rats.

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0037-Z

21 January 2018

Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0037-Z

21 January 2018

Expression, bioactivity, and safety 1 year after adeno-associated viral vector type 2-mediated delivery of neurturin to the monkey nigrostriatal system support cere-120 for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0037-Z

21 January 2018

The aged monkey basal forebrain: rescue and sprouting of axotomized basal forebrain neurons after grafts of encapsulated cells secreting human nerve growth factor

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0037-Z

21 January 2018

Neural grafting in the aged rat brain

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0037-Z

21 January 2018

Age-associated neuronal atrophy occurs in the primate brain and is reversible by growth factor gene therapy

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0037-Z

21 January 2018

Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0037-Z

21 January 2018

Immune responses to AAV in a phase I study for Canavan disease.

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0037-Z

21 January 2018

Clinical protocol. Administration of a replication-deficient adeno-associated virus gene transfer vector expressing the human CLN2 cDNA to the brain of children with late infantile neuronal ceroid lipofuscinosis

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0037-Z

21 January 2018

Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0037-Z

21 January 2018

AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0037-Z

21 January 2018

Results from a phase I safety trial of hAADC gene therapy for Parkinson disease

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0037-Z

21 January 2018

Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0037-Z

21 January 2018

Parkinson's disease. Second of two parts

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0037-Z

21 January 2018

The scientific and clinical basis for the treatment of Parkinson disease (2009).

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0037-Z

21 January 2018

Carrier mediated delivery of NGF: alterations in basal forebrain neurons in aged rats revealed using antibodies against low and high affinity NGF receptors

1 reference

https://pubmed.ncbi.nlm.nih.gov/25788422

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Age-related changes in the capacity, rate, and modulation of dopamine uptake within the striatum and nucleus accumbens of Fischer 344 rats: an in vivo electrochemical study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25788422

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The blood-brain barrier as a target for pharmacological modulation.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25788422

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: support for nigral targeting in Parkinson's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/25788422

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: A randomized controlled trial. rhNGF Clinical Investigator Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/25788422

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sustained delivery of proteins for novel therapeutic agents

1 reference

https://pubmed.ncbi.nlm.nih.gov/25788422

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intrathecal ciliary neurotrophic factor delivery for treatment of amyotrophic lateral sclerosis (phase I trial).

1 reference

https://pubmed.ncbi.nlm.nih.gov/25788422

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The functional observational battery in adult and developing rats

1 reference

https://pubmed.ncbi.nlm.nih.gov/25788422

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. NGF Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/25788422

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A 2-year comparison study of Crl:CD BR and Hsd:Sprague-Dawley SD rats

1 reference

https://pubmed.ncbi.nlm.nih.gov/25788422

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Systemic administration of a nerve growth factor conjugate reverses age-related cognitive dysfunction and prevents cholinergic neuron atrophy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25788422

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25788422

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adeno-Associated Virus (AAV) Vectors in the CNS

1 reference

https://pubmed.ncbi.nlm.nih.gov/25788422

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S13346-011-0037-Z

1 reference

Europe PubMed Central

PubMed publication ID

28 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41195395&oldid=2094183074"